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ABSTRACT
The widespread circulation of highly pathogenic avian influenza viruses (HPAIVs) and their occasional transmission to humans 
creates a constant pandemic threat and leads to significant economic losses in the poultry industry. The development of an ef-
fective and safe vaccine for the broad protection of poultry from H5N1 HPAIVs remains an important goal. Prevention of the virus 
transmission between ducks and chickens is important for the efficient control of the spread of avian influenza. The oral admin-
istration of live vaccines corresponds to the natural route of infection that leads to virus replication in the intestinal epithelial 
cells that cause a well-balanced and broad immune response providing protection against the viruses of distant clades. The broad 
protection is the important advantage of live-attenuated influenza vaccines when compared to inactivated ones. Here, we give an 
overview of the latest approaches and results in the development of live poultry vaccine candidates against HPAIVs.
INTRODUCTION
The widespread circulation of HPAIVs causes significant 
economic losses in the poultry industry while the oc-
casional transmission of these viruses to humans poses 
a continuous pandemic threat. In December 2014, the 
Eurasian HPAIVs of H5N8 and H5N2 subtypes reached 
United States (US) and caused the largest animal health 
emergency in US history resulting in death or the culling 
of more than 48 million birds [1].
Currently, the outbreaks of the HPAIVs are mainly 
controlled by the culling of all the birds in the affected 
regions. Vaccination can serve as a preventive measure to 
combat the virus infection in birds instead of eradication 
[2]. Thus, tens of billions of doses of inactivated vaccine 
in the form of oil-in-water emulsion containing whole 
virus with adjuvant were used in affected countries, par-
ticularly in China. This inactivated vaccine was based on 
reassortants engineered by reverse genetics, which con-
tain the H5 hemagglutinin (HA) and N1 neuraminidase 
(NA) from H5N1 viruses and the remaining genes from 
A/Puerto Rico/8/1934 (PR8) virus [3, 4].
Inefficiency of inactivated vaccines 
in the prevention of virus spreading 
The widespread campaigns of poultry vaccination with 
H5N1 vaccine unfortunately failed to prevent the long-
distance transition of HPAIVs of H5 subtype. The im-
munization with inactivated virus did not prevent virus 
shedding in birds after being challenged by HPAIVs [5-8]. 
Therefore, the inactivated vaccines successfully protect-
ed layers and broiler chickens from disease and prevented 
the decrease in egg production but did not prevent the 
spread of the virus.
Influenza virus of the H9N2 subtype also continues to 
circulate in vaccinated chicken flocks in China because 
the protective efficacy of inactivated vaccines against 
antigenic drift variants is limited [9]. Since the effective-
ness of inactivated vaccines strongly depends on the an-
tigenic match of the HA in the vaccine and the HA of the 
field virus, the antigenic diversity of avian influenza vi-
ruses has been recognized as the main challenge for the 
eradication of HPAIVs [9-12]. 
The potential advantages of live attenuated 
influenza vaccines (LAIVs) 
The use of live influenza vaccines offers substantial ben-
efits compared to inactivated ones. The oral administra-
tion of live vaccines leads to the replication of the virus 
in epithelial cells and causes a well-balanced and broad 
immune response providing protection against the vi-
ruses of distant clades [13]. 
LAIVs have several advantages over traditional inacti-
vated influenza vaccines. These vaccines can be produced 
rapidly, safely, and inexpensively [4, 14, 15]. It is generally 
recognized that live vaccines are superior to inactivated vac-
cines in preventing the circulation of the virus. The broad 
protection of live vaccines is ensured  by development of 
both the humoral and cellular immunity to virus that rep-
licates in relevant tissues. Moreover, mass vaccination with 
LAIV could be accomplished easily [4]. Today, several known 
approaches are used to develop live influenza vaccines.
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Recombinant vector vaccines
A number of live recombinant H5N1 influenza vaccines 
have been developed using live virus vectors, such as 
duck enteritis virus (DEV), turkey herpes virus (HVT), 
Newcastle disease virus (NDV), fowlpox virus (FPV), and 
infectious laryngotracheitis virus (ILTV). These vaccines 
are cost effective and can provide protection against two 
viral diseases simultaneously [15, 16]. 
A polyvalent candidate vectored vaccine based on 
DEV carrying the HA gene from A/duck/Hubei/xn/2007 
(H5N1) virus was developed by Zou et al. [17]. Ducks im-
munized with this live vaccine were shown to develop a 
long-lasting protection against homologous and heter-
ologous H5N1 HPAIVs and DEV. 
Live recombinant vector vaccine based on the HVT 
expressing the HA of H5N1 HPAIV was developed by 
Rauw et al. [18]. This vaccine protected vaccinated birds 
from challenge with the homologous and heterologous 
HPAIVs of H5N1 and H5N2 subtypes [19]. Recombinant 
HVT provided higher protection than the inactivated 
vaccine in the form of oil-in-water emulsion produced 
from a similar strain [20]. 
Live recombinant vector vaccine based on the HVT 
expressing the HA of H5N1 HPAIV (rHVT-H5/2.2) was 
examined in Pekin ducks and showed only 30% mortal-
ity reduction for the birds challenged with H5N1 HPAIV. 
When used together with an inactivated vaccine in a 
prime-boost regiment it provided only a minor additive 
effect on the reduction of virus shedding [21]. 
Tang et al. suggested that CRISPR/Cas9-based genome 
editing could be used as a powerful tool for the generation 
of the HVT recombinants expressing viral antigens [22].
In another effort to create a live vector vaccine, the 
NDV recombinant virus expressing the HA of HPAIV 
(H5N1) was generated. This recombinant virus protected 
chickens against lethal infection with H5N1 virus after 
the first immunization [23]. Immunization of chickens 
with NDV-vectored H5N1 vaccine provided a high level of 
protection against the clinical disease and mortality after 
lethal challenge with HPAIV of H5N1 subtype [24]. The 
NDV-vectored H7 and H5 vaccines were able to induce 
high antibody titers and completely protect chickens 
from challenge with the novel H7N9 and highly patho-
genic H5N1 viruses [25]. The chimeric NDV vectored vac-
cine expressing the HA of A/Vietnam/1203/2004 (H5N1) 
was safe for 1-day-old chickens and provided a partial 
protection against challenge with A/Vietnam/1203/2004 
HPAIV indicating the possibility of the early protection of 
chickens [26]. The NDV-based H5 vaccine that expressed 
a codon-optimized ectodomain of the HA of A/chicken/
Iowa/04-20/2015 (H5N2) virus was also shown to be ef-
fective in chickens, demonstrating a lack of clinical signs 
and virus shedding after the challenge with HPAIV A/tur-
key/Minnesota/9845-4/2015 (H5N2) [27]. Thus, this type 
of vaccine can protect chickens against intercontinental 
HPAIVs of H5Nx subtype and, therefore, can be used for 
the mass vaccination of poultry. However, the pre-ex-
isting immunity to NDV vector of commercial chickens 
should be taken into consideration because it can reduce 
the vaccine efficacy. 
Bacterial vectors can also be used to construct recom-
binant vaccines. One of the examples is the attenuated 
Salmonella gallinarum vaccine candidate, expressing the 
globular head (HA1) domain of H5 HA of low pathogenic 
avian A/spot-billed duck/Korea/KNU SYG06/2006 (H5N3) 
influenza virus. The immunization of chickens with this 
vaccine candidate demonstrated the faster clearance of 
H5N3 challenge virus. This recombinant vaccine can be 
used as a bivalent preparation against fowl typhoid and 
influenza diseases [28]. 
An attenuated strain of Salmonella typhimurium de-
signed for the expression and delivery of H7N9 HA, NA, 
or the conserved extracellular domain of the matrix pro-
tein 2 (M2e) was constructed by Kim et al. [29]. It was 
shown that these vaccine candidates are safe and im-
munogenic in chickens. The single oral immunization of 
chickens with one or several strains expressing HA, NA, 
or M2e induced protective immunity against the lethal 
challenge with H7N9 virus.
Vaccines with truncated NS1 gene 
One of the approaches for the generation of the attenuat-
ed influenza vaccine strain is the truncation of a gene en-
coding the nonstructural (NS) protein NS1. It was shown 
that the vaccine candidates carrying the shortened NS1 
gene are attenuated and protective against homologous 
and heterologous HPAIVs in animal models [30]. The high 
efficacy of NS1-truncated LAIV correlates well with the 
upregulation of interferon (IFN)-stimulated genes (ISGs) 
that promotes the rapid induction of adaptive immune 
response against influenza in chickens and increases the 
protective effect of vaccine [31].
It was shown that the mutant influenza virus lack-
ing NS1 protein (named delNS1) is highly attenuated in 
IFN-competent subjects [32-35]. Poor virus replication 
and lack of disease symptoms following the delNS1 vi-
rus immunization were accompanied by an enhanced 
IFN induction. Therefore, the viruses with NS1 deletion 
or truncated NS1 gene are attenuated for animal hosts 
and could be used as live attenuated vaccine candidates. 
Using this approach, a number of vaccine viruses were 
produced and their effectiveness was demonstrated in 
mice and chickens.
The properties of H5N1 avian influenza virus reas-
sortants with NS1 protein terminated at amino acids (aa) 
48, 70, 73, or 99, along with a modified HA protein were 
analyzed by Shi et al. [36]. The recombinant virus with 
NS1, truncated at aa 73, demonstrated the protection of 
chickens from the broad range of H5N1 influenza viruses. 
A dual LAIV carrying viruses with HA and NA genes from 
an avian H5N2 and H9N2 viruses, constructed on the PR8 
backbone with truncated NS1 genes was attenuated in 
mice [37]. This vaccine induced a powerful IFNβ response 
and completely protected mice from a lethal challenge 
with heterologous highly pathogenic H5N1 virus and 
highly virulent virus of H9N2 subtype.
The mutant virus of H9N2 subtype with NS1-128 
truncation was more immunogenic than the correspond-
ing inactivated vaccine and protected chickens from 
challenge by homologous and heterologous H9N2 avian 
influenza viruses [38]. 
Live influenza poultry vaccines
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Vaccines based on temperature-sensitive mutants
The attenuation of influenza virus through the acquisi-
tion of temperature-sensitive mutations is another ap-
proach for the generation of live influenza vaccines [39]. 
Live cold-adapted influenza vaccine candidates were 
developed by serial passages of H9N2 viruses in chicken 
embryos at low temperature. It was shown that the ob-
tained mutant viruses protect chickens from homolo-
gous and heterologous strains of H9N2 subtype [9, 40]. 
Hickmann et al. constructed the live attenuated avian 
influenza vaccine candidate on the base of genetically 
modified temperature-sensitive A/guinea fowl/Hong 
Kong/WF10/1999 (H9N2) strain carrying the mutations 
in PB1 and PB2 genes [41]. Genes encoding the HA and 
NA antigens of vaccine candidate were originated from 
the Asian H5N1 virus. This virus was administered in ovo 
to 18-day-old chicken embryos. Challenge of the hatched 
chickens with HPAIV of H5N1 subtype led to 60% protec-
tion for the 4-week-old chickens and to 100% protection 
for the 9-12-week-old birds.
Another vaccine candidate comprising the genes that 
encode the internal proteins from a cold-adapted influ-
enza virus A/chicken/Korea/S1/2003 (H9N2) (obtained by 
serial passages in chicken embryos at 25°C) and HA and 
NA genes from a highly pathogenic H5N1 influenza virus 
was generated by Lee et al. [42]. The immunized chickens 
developed substantial humoral and cellular immunity 
and were protected from lethal challenge with the ho-
mologous and heterologous influenza viruses of H5N1 or 
H9N2 subtypes.
Pena et al. reported that a vaccine strain with the re-
arranged genome of an avian H9N2 influenza virus that 
expressed the H5 HA open reading frame (ORF) from the 
segment 8 viral RNA protected mice and ferrets against 
lethal H5N1 challenge as well as against a potentially 
pandemic H9 virus [43]. 
Vaccine lacking neuraminidase protein
A novel live experimental H5 vaccine candidate EscE-
gg50A lacking the NA protein was developed by pas-
saging of HPAIV A/Cygnus cygnus/Germany/R65/2006 
(H5N1) in embryonated chicken eggs in the presence of 
a neutralizing serum. The resulting mutant strain lost 
the large section of the gene encoding NA but preserved 
the polybasic cleavage site in the HA protein. A single 
immunization of chickens, mice, and ferrets with this vi-
rus seven and three days before a lethal challenge with 
A/Cygnus cygnus/Germany/R65/2006 protected all the 
animals from the signs of disease and virus shedding [44]. 
The examples presented here confirm that live influ-
enza vaccine could be more effective in the protection 
of birds against circulating drift variants and in the pre-
vention of virus spreading when compared to inactivated 
vaccine. 
Live vaccines made from viruses with genes 
of apathogenic avian viruses
Considering the low virulence of naturally selected low 
pathogenic avian influenza viruses (LPAIVs) isolated 
from waterfowls, many researchers tried to use the genes 
of these viruses for the development of live influenza 
vaccines. For the first time, this approach was used by 
Murphy et al. for the generation of live attenuated reas-
sortants between low pathogenic avian and human in-
fluenza A viruses [45, 46]. Oral immunization of chickens 
with a live waterfowl-originated avian H5N9 influenza 
virus effectively protected birds from lethal challenge 
with H5 virus and prevented cloacal shedding of the vi-
rus [47]. 
A new approach for the expression and/or delivery 
of foreign antigens was developed by the substitution of 
the extracellular domain of the low pathogenic avian A/
chicken/Jiangsu/11/2002 (H9N2) virus M2 protein with 
the HA1 from PR8 virus [48]. The resulting hybrid virus 
named H9N2-PR8/HA1 had low pathogenicity and was 
genetically stable. Intranasal immunization of Balb/c 
mice with H9N2-PR8/HA1 induced both anti-H9N2 and 
anti-PR8 HA antibodies and provided protection against 
lethal challenge with either H1N1 or H9N2 viruses.
The avian influenza virus A/duck/Zhejiang/1028/2009 
(H7N3) isolated from ducks was evaluated as a potential 
live influenza vaccine candidate. This virus turned out to 
be low pathogenic and immunogenic for mice and chick-
ens after intranasal administration [14]. The presented 
data suggest that the duck influenza virus could be used 
as a candidate for the development of a live vaccine in 
order to mitigate the severity of the possible pandemic 
that could be caused by the newly emerging H7N9 virus. 
Parallel evaluation of different live influenza vaccine 
candidates
Parallel evaluation of apathogenic wild duck influenza 
virus А/duck/Moscow/4182/2010 (H5N3, named dk/4182) 
and attenuated experimental reassortants made on the 
base of different donors was conducted in order to com-
pare their safety, immunogenicity, and protective efficacy 
against H5N1 HPAIV [49, 50]. Two experimental reassor-
tants were constructed on the base of cold-adapted mas-
ter strain of LAIV for humans A/Leningrad/134/17/1957 
(H2N2) (Len). These reassortants inherited all the genes 
from the master strain Len except the gene encoding the 
HA. The gene encoding the HA was originated from the A/
Vietnam/1203/2004 (H5N1) (VN) strain lacking the poly-
basic HA cleavage site, or from the H5N1 virus A/chick-
en/Kurgan/3/2005 (Ku/wt) attenuated by means of the 
amino acid substitutions 54Asp→Asn and 222Lys→Thr 
in НА1 and 48Val→Ile and 131Lys→Thr in НА2 while 
maintaining the polybasic HA cleavage site (named Ku/
att). These reassortants were named as VN-Len and Ku-
Len, respectively. 
Two more reassortants were generated on the base 
of apathogenic H6N2 virus A/gull/Moscow/3100/2006. 
These viruses inherited the same HA genes as two virus-
es described above – from VN and Ku/att viruses respec-
tively, while all the other genes were originated from A/
gull/Moscow/3100/2006 virus. The obtained reassortants 
were named as VN-Gull and Ku-Gull respectively [51-54]. 
All obtained viruses were tested in chickens using in-
travenous, intranasal, aerosol, and oral routes of infec-
tion and proved to be apathogenic for chickens. Viruses 
VN-Len and Ku-Len were over-attenuated for chickens 
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[39, 55] and did not provide reliable protection from le-
thal challenge with HPAIV [49, 50]. In contrast, the virus-
es VN-Gull and Ku-Gull ensured the complete protection 
of chickens. However, these viruses were not attenuated 
enough and caused the partial death of 1-day-old chicks. 
On the contrary, the wild duck virus dk/4182 was safe, 
highly immunogenic and protective in chickens regard-
less of inoculation route. 
The impact of the vaccine dose and age of chickens on the 
vaccination efficacy 
Vaccine administration via drinking water is an attrac-
tive way for the immunization of poultry. To explore the 
capabilities of this method of vaccination, the dk/4182 
virus was tested as a live oral vaccine candidate. The im-
pact of vaccine dose and the age of chickens on the vacci-
nation efficacy were studied in order to find the optimal 
immunization conditions.
Single immunization of 30-day-old chickens with 
106 TCID50 (tissue culture infective dose 50) of dk/4182 
virus via drinking water completely protected chickens 
from the lethal dose (100  LD50) of the HPAIV of H5N1 
subtype [56]. The antibody response to immunization 
with lower doses varied between the birds and was con-
sidered unsatisfactory. Young chickens (10-day-old or 
younger) showed the weak humoral immune response 
to the vaccination. The vaccination of chickens older 
than 20 days resulted in reasonable antibody titers. All 
the chickens that were vaccinated twice on the 7th and 
30th day after hatching showed a high and stable anti-
body response. 
Shedding and transmission of dk/4182 and Ku/wt viruses 
in chickens and ducks
Ducks and chickens infected with Ku/wt or dk/4182 vi-
ruses shed the viruses in feces from day 3 to day 10 post 
infection. Despite that, contact of infected birds with un-
infected chickens led to their infection with Ku/wt virus 
but did not result in infection with dk/4182 as they did 
not excrete this virus and did not develop antibodies to 
it. These results can be explained by the fact that a very 
high dose of dk/4182 virus is required for the productive 
infection in chickens. In contrast, the chickens being in 
contact with the ducks infected with Ku/wt virus became 
sick, shed the virus, and died [57]. When ducks were pri-
marily infected with dk/4182 and challenged with H5N1 
HPAIV from 14 to 90 days after infection, the challenge 
virus was not found in their feces. Naïve chickens that 
were placed in contact with these ducks did not show any 
signs of the disease, any excretion of the virus with feces, 
or present any antibody response. 
These results show that the low pathogenic virus of 
wild aquatic birds dk/4182 can prevent the transmission 
of H5N1 viruses between ducks and chickens. 
Perspectives of use of live poultry vaccines against 
H5N1 HPAIV
The potential risk of the restoration of pathogenicity 
of the attenuated vaccine strain is the reason for the 
existing strong regulatory barriers against live poultry 
vaccines created from avian influenza viruses [4]. It is 
believed that reverse mutations could restore the viru-
lence of a vaccine virus. Indeed, it has been shown that 
outbreaks of HPAIVs in Pennsylvania (1983-84), Mexico 
(1994-95), and Italy (1999-2000) were caused by original-
ly non-virulent viruses that became highly pathogenic in 
the course of circulation in poultry [58]. However, phy-
logenetic analyses of these viruses showed that all the 
mentioned episodes of rapid acquisition of pathogenic-
ity happened when the low-pathogenic avian predeces-
sors were closely related to pathogenic poultry viruses 
and had been recently reintroduced into natural wild bird 
reservoir [59]. 
The emergence of a new evolutionary branch of 
HPAIVs is a rare phenomenon. Wild bird influenza virus-
es do not cause disease in their natural host waterfowls. 
Wild ducks differ from chickens in terms of ecology and 
spreading of influenza viruses. The duck-adapted virus-
es derived from the natural reservoir in contrast to the 
poultry-adapted viruses, do not replicate effectively in 
poultry. All attempts to propagate the LPAIV A/whistling 
swan/Shimane/499/83 (H5N3) by intranasal, intratrache-
al, and intracerebral inoculation into 1-day-old chickens 
were unsuccessful. This virus acquired partial virulence 
in 2-day-old chickens only after 11 passages through air 
sacs [60]. The virus dk/4182 also poorly replicated in the 
internal organs of chickens and and was not transmit-
ted to contact birds. One of the factors of the virus host 
range restriction is the pH at which the HA undergoes 
the conformational change necessary for the fusion of vi-
rus and cellular membranes in order to deliver the virus 
genome to the cytoplasm. This pH is known as the pH 
of fusion or pH of activation. Virus dk/4182 as a typical 
duck virus is characterized by a low pH of fusion (pH 5.2), 
which makes it resistant to the acidic pH of the intestinal 
tract – the main site of virus replication. Chicken viruses, 
on the contrary, have an elevated pH of fusion (pH 5.6-
5.8) and, therefore, are unstable at acidic pH. Chicken vi-
ruses replicate predominantly in the oropharyngeal tract 
and viruses with the polybasic cleavage site disseminate 
to other internal organs [50].
Phylogenetic analysis of the full-length genomic se-
quences showed that all the genes of dk/4182 virus be-
long to evolutionary clades containing exclusively low 
pathogenic viruses of wild aquatic birds. Since dk/4182 
virus is antigenically equidistant from all HPAI H5 vi-
ruses, it is likely that vaccine based on this virus should 
be effective against a broad range of H5 HPAIVs [49, 50]. 
Since the administration of dk/4182 H5N3 to chi ck-
ens and ducks via drinking water ensured the complete 
protection of birds from lethal viral challenges and pre-
vented the transmission of the challenge virus, one can 
conclude that the dk/4182 H5N3 virus represents a prom-
ising candidate for the development of a live vaccine for 
the protection of poultry from H5N1 HPAI viruses [56, 
57].
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